PubRank

Kevin Shannon

Author PubWeight™ 72.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007 10.27
2 Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006 4.48
3 Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2007 3.11
4 K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 2006 1.93
5 Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 2007 1.89
6 Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013 1.85
7 Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009 1.72
8 A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med 2011 1.72
9 Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009 1.67
10 p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010 1.66
11 Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2010 1.60
12 Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer 2006 1.54
13 Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest 2012 1.52
14 Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev 2007 1.48
15 Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 2007 1.41
16 Use of a donor heart with symptomatic WPW in an alternate donor program. J Heart Lung Transplant 2002 1.39
17 Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010 1.36
18 Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 2006 1.35
19 Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A 2010 1.25
20 Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2013 1.19
21 Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative to cardiac surgery. Heart Rhythm 2004 1.15
22 Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov 2013 1.13
23 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005 1.08
24 Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 2011 1.08
25 Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 2008 1.07
26 Targeting Ras in myeloid leukemias. Clin Cancer Res 2008 1.07
27 Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Exp Hematol 2002 1.06
28 Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood 2006 1.06
29 Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002 1.03
30 De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 2007 1.02
31 Targeting oncogenic Ras. Genes Dev 2007 1.01
32 Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci Signal 2013 0.98
33 Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res 2011 0.93
34 Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood 2010 0.90
35 Equivalent performance of epicardial versus endocardial permanent pacing in children: a single institution and manufacturer experience. Ann Thorac Surg 2008 0.88
36 Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med 2005 0.86
37 Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 2002 0.83
38 Sending out an SOS. Nat Genet 2007 0.82
39 PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 2013 0.82
40 IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci U S A 2003 0.82
41 Evaluation of safety and efficacy of pacemaker and defibrillator implantation by axillary incision in pediatric patients. Pacing Clin Electrophysiol 2004 0.81
42 Prevalence of ADHD symptoms in patients with congenital heart disease. Pediatr Int 2012 0.80
43 Mouse cancer models as a platform for performing preclinical therapeutic trials. Curr Opin Genet Dev 2003 0.79
44 HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res Hum Retroviruses 2002 0.79
45 Genetics, epigenetics, and leukemia. N Engl J Med 2010 0.78
46 Tumor suppressor gene inactivation in myeloid malignancies. Best Pract Res Clin Haematol 2008 0.78
47 Arrhythmia recurrence in adult patients with single ventricle physiology following surgical Fontan conversion. Congenit Heart Dis 2010 0.78
48 Implantable cardioverter-defibrillators and the young athlete: can the two coexist? Pediatr Cardiol 2012 0.77
49 A novel approach to eliminate intraventricular lead placement in patients with congenital heart disease. J Interv Card Electrophysiol 2012 0.77
50 Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer 2014 0.76
51 De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. BMJ Case Rep 2009 0.76
52 Cancer: More than kin and less than kind. Nature 2009 0.75
53 Advancing the STATus of MPN pathogenesis. Blood 2012 0.75
54 The SPS affair: a complex tale of illicit proliferation. Cancer Cell 2009 0.75
55 The sum is greater than the FGFR1 partner. Cancer Cell 2004 0.75
56 The vibrational mode structure of a golf ball. J Sports Sci 2002 0.75
57 Inappropriate sinus tachycardia after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2010 0.75
58 Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest 2016 0.75